Versor Investments LP Purchases Shares of 7,179 DaVita Inc. (NYSE:DVA)

Versor Investments LP bought a new position in DaVita Inc. (NYSE:DVA - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,179 shares of the company's stock, valued at approximately $1,177,000.

A number of other institutional investors have also recently added to or reduced their stakes in DVA. Harvard Management Co. Inc. acquired a new position in DaVita in the 2nd quarter worth approximately $55,115,000. Lazard Asset Management LLC boosted its stake in shares of DaVita by 147.3% during the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company's stock valued at $35,460,000 after buying an additional 153,008 shares during the period. Andra AP fonden grew its holdings in shares of DaVita by 9.0% during the 2nd quarter. Andra AP fonden now owns 192,300 shares of the company's stock valued at $26,647,000 after acquiring an additional 15,800 shares in the last quarter. abrdn plc grew its stake in shares of DaVita by 1.2% in the 3rd quarter. abrdn plc now owns 189,065 shares of the company's stock valued at $30,719,000 after buying an additional 2,180 shares in the last quarter. Finally, Jupiter Asset Management Ltd. lifted its stake in DaVita by 146.7% in the first quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company's stock valued at $25,840,000 after acquiring an additional 111,311 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Michael David Staffieri sold 9,539 shares of the company's stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the sale, the chief operating officer now owns 241,945 shares in the company, valued at $36,299,008.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, COO Michael David Staffieri sold 9,539 shares of the company's stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares in the company, valued at approximately $36,299,008.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Javier Rodriguez sold 9,881 shares of the firm's stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the sale, the chief executive officer now directly owns 887,835 shares in the company, valued at $144,583,929.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 165,625 shares of company stock worth $26,238,297 in the last 90 days. Corporate insiders own 2.00% of the company's stock.

DaVita Trading Up 2.3 %

DVA stock traded up $3.55 during midday trading on Tuesday, reaching $158.03. The stock had a trading volume of 1,002,720 shares, compared to its average volume of 819,685. The firm has a market cap of $12.96 billion, a price-to-earnings ratio of 16.66, a PEG ratio of 0.84 and a beta of 0.89. DaVita Inc. has a twelve month low of $84.64 and a twelve month high of $168.50. The business has a fifty day simple moving average of $157.22 and a two-hundred day simple moving average of $147.05. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.85 earnings per share. As a group, research analysts expect that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on DVA shares. UBS Group upped their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research report on Wednesday, August 7th. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research report on Monday, October 7th. TD Cowen increased their target price on DaVita from $139.00 to $150.00 and gave the stock a "hold" rating in a report on Wednesday, July 24th. Finally, Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.